The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: A quantitative proteomic based study

Journal of Proteomics

Volumn 106, Issue , 2014, Pages 99-112

  Liu, Yi ^a   Wang, Xiwei ^a   Li, Sanglin ^a   Hu, Huaidong ^a,b   Zhang, Dazhi ^a,b   Hu, Peng ^a,b   Yang, Yixuan ^a,b   Ren, Hong ^a,b  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; Isobaric tags for relative and absolute quantitation; Von Willebrand factor

Indexed keywords

INTERFERON; SMALL INTERFERING RNA; VON WILLEBRAND FACTOR; APOLIPOPROTEIN E; BIOLOGICAL MARKER; FRUCTOSE BISPHOSPHATE ALDOLASE; PROTEOME; SERUM AMYLOID A;

ADULT; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR INVASION; VIRUS REPLICATION; WESTERN BLOTTING; BLOOD; CELL MOTION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE SILENCING; LIVER TUMOR; METABOLISM; MIDDLE AGED; TUMOR CELL LINE; VIROLOGY;

ADULT; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; FEMALE; FRUCTOSE-BISPHOSPHATE ALDOLASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASM INVASIVENESS; PROTEOME; PROTEOMICS; RNA, SMALL INTERFERING; SERUM AMYLOID A PROTEIN; SIGNAL TRANSDUCTION; VON WILLEBRAND FACTOR;

EID: 84900020220     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.04.021     Document Type: Article

References (62)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. Beasley R.P., Hwang L.Y., Lin C.C., Chien C.S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981, 2:1129-1133.
4. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118:3030-3044.
5. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
6. Sherman M., Peltekian K.M., Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995, 22:432-438.
7. Marrero J.A., Feng Z., Wang Y., Nguyen M.H., Befeler A.S., Roberts L.R., et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009, 137:110-118.
8. Sterling R.K., Jeffers L., Gordon F., Sherman M., Venook A.P., Reddy K.R., et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol 2007, 102:2196-2205.
9. Marrero J.A., Su G.L., Wei W., Emick D., Conjeevaram H.S., Fontana R.J., et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003, 37:1114-1121.
10. Ishizuka H., Nakayama T., Matsuoka S., Gotoh I., Ogawa M., Suzuki K., et al. Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-l-fucosidase activity. Intern Med 1999, 38:927-931.
11. Tremosini S., Forner A., Boix L., Vilana R., Bianchi L., Reig M., et al. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut 2012, 61:1481-1487.
12. Di Bisceglie A.M., Hoofnagle J.H. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989, 64:2117-2120.
13. Beretta L. Proteomics from the clinical perspective: many hopes and much debate. Nat Methods 2007, 4:785-786.
14. Klose J., Kobalz U. Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome. Electrophoresis 1995, 16:1034-1059.
15. Bouchal P., Roumeliotis T., Hrstka R., Nenutil R., Vojtesek B., Garbis S.D. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. J Proteome Res 2009, 8:362-373.
16. Jankova L., Chan C., Fung C.L., Song X., Kwun S.Y., Cowley M.J., et al. Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. Mol Biosyst 2011, 7:2997-3005.
17. Pernemalm M., De Petris L., Eriksson H., Branden E., Koyi H., Kanter L., et al. Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion. Proteomics 2009, 9:3414-3424.
18. Garbis S.D., Tyritzis S.I., Roumeliotis T., Zerefos P., Giannopoulou E.G., Vlahou A., et al. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2008, 7:3146-3158.
19. Chong P.K., Lee H., Loh M.C., Choong L.Y., Lin Q., So J.B., et al. Upregulation of plasma C9 protein in gastric cancer patients. Proteomics 2010, 10:3210-3221.
20. Pawar H., Kashyap M.K., Sahasrabuddhe N.A., Renuse S., Harsha H.C., Kumar P., et al. Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biol Ther 2011, 12:510-522.
21. Rai A.J., Gelfand C.A., Haywood B.C., Warunek D.J., Yi J., Schuchard M.D., et al. HUPO plasma proteome project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005, 5:3262-3277.
22. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
23. Liaw Y.-F., Kao J.-H., Piratvisuth T., Chan H.L.Y., Chien R.-N., Liu C.-J., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012, 6:531-561.
24. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010, 53:397-417.
25. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
26. Edge S.B., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti A. AJCC Cancer Staging Handbook 2010, Springer-Verlag New York Inc., New York. 7th ed.
27. Yang Y., Lim S.K., Choong L.Y., Lee H., Chen Y., Chong P.K., et al. Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins. J Proteome Res 2010, 9:4767-4778.
28. Tong S.W., Yang Y.X., Hu H.D., An X., Ye F., Hu P., et al. Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line. J Cell Biochem 2012, 113:1671-1680.
29. Gan C.S., Chong P.K., Pham T.K., Wright P.C. Technical, experimental, and biological variations in isobaric tags for relative and absolute quantitation (iTRAQ). J Proteome Res 2007, 6:821-827.
30. Zhou C., Simpson K.L., Lancashire L.J., Walker M.J., Dawson M.J., Unwin R.D., et al. Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery. J Proteome Res 2012, 11:2103-2113.
31. Xie T.X., Wei D., Liu M., Gao A.C., Ali-Osman F., Sawaya R., et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23:3550-3560.
32. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.
33. Ganem D., Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004, 350:1118-1129.
34. Ioannou G.N., Splan M.F., Weiss N.S., McDonald G.B., Beretta L., Lee S.P. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007, 5:938-945. [45 e1-4].
35. Vischer U.M., von Wagner D.D. Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood 1994, 83:3536-3544.
36. Franchini M., Lippi G. The role of von Willebrand factor in hemorrhagic and thrombotic disorders. Crit Rev Clin Lab Sci 2007, 44:115-149.
37. Knittel T., Neubauer K., Armbrust T., Ramadori G. Expression of von Willebrand factor in normal and diseased rat livers and in cultivated liver cells. Hepatology 1995, 21:470-476.
38. Nierodzik M.L., Kajumo F., Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 1992, 52:3267-3272.
39. Morganti M., Carpi A., Amo-Takyi B., Sagripanti A., Nicolini A., Giardino R., et al. Von Willebrand's factor mediates the adherence of human tumoral cells to human endothelial cells and ticlopidine interferes with this effect. Biomed Pharmacother 2000, 54:431-436.
40. Bruggemann L.W., Versteeg H.H., Niers T.M., Reitsma P.H., Spek C.A. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med 2008, 12:2622-2627.
41. Hatzipantelis E.S., Athanassiou-Metaxa M., Gombakis N., Tzimouli V., Taparkou A., Sidi-Fragandrea V., et al. Thrombomodulin and von Willebrand factor: relation to endothelial dysfunction and disease outcome in children with acute lymphoblastic leukemia. Acta Haematol 2011, 125:130-135.
42. Paczuski R., Bialkowska A., Kotschy M., Burduk D., Betlejewski S. von Willebrand factor in plasma of patients with advanced stages of larynx cancer. Thromb Res 1999, 95:197-200.
43. Wang W.S., Lin J.K., Lin T.C., Chiou T.J., Liu J.H., Yen C.C., et al. Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. World J Gastroenterol 2005, 11:2166-2170.
44. Koh S.C., Khalil R., Lim F.K., Ilancheran A., Choolani M. The association between fibrinogen, von Willebrand Factor, antithrombin III, and d-dimer levels and survival outcome by 36months from ovarian cancer. Clin Appl Thromb Hemost 2006, 12:3-8.
45. Josefsson A., Wikstrom P., Granfors T., Egevad L., Karlberg L., Stattin P., et al. Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol 2005, 48:577-583.
46. Jiang W.G., Watkins G., Douglas-Jones A., Holmgren L., Mansel R.E. Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. BMC Cancer 2006, 6:16.
47. Kim S.M., Myoung H., Choung P.H., Kim M.J., Lee S.K., Lee J.H. Metastatic leiomyosarcoma in the oral cavity: case report with protein expression profiles. J Craniomaxillofac Surg 2009, 37:454-460.
48. Yoon S., Woo S.U., Kang J.H., Kim K., Shin H.J., Gwak H.S., et al. NF-kappaB and STAT3 cooperatively induce IL6 in starved cancer cells. Oncogene 2012, 31:3467-3481.
49. Subramaniam A., Shanmugam M.K., Perumal E., Li F., Nachiyappan A., Dai X., et al. Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta 1835, 2013:46-60.
50. Senft C., Priester M., Polacin M., Schroder K., Seifert V., Kogel D., et al. Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol 2011, 101:393-403.
51. Pramhas S., Homoncik M., Ferenci P., Ferlitsch A., Scherzer T., Gangl A., et al. von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4. Antivir Ther 2010, 15:831-839.
52. Park Y., Park Y., Han K.H., Kim H.S. Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy. J Clin Lab Anal 2011, 25:414-421.
53. Petri B., Broermann A., Li H., Khandoga A.G., Zarbock A., Krombach F., et al. von Willebrand factor promotes leukocyte extravasation. Blood 2010, 116:4712-4719.
54. Schindler C., Levy D.E., Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007, 282:20059-20063.
55. Wang W.B., Levy D.E., Lee C.K. STAT3 negatively regulates type I IFN-mediated antiviral response. J Immunol 2011, 187:2578-2585.
56. Shimizu Y., Hishiki T., Ujino S., Sugiyama K., Funami K., Shimotohno K. Lipoprotein component associated with hepatitis C virus is essential for virus infectivity. Curr Opin Virol 2011, 1:19-26.
57. Moriya K., Fujie H., Shintani Y., Yotsuyanagi H., Tsutsumi T., Ishibashi K., et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4:1065-1067.
58. Chen Y.C., Pohl G., Wang T.L., Morin P.J., Risberg B., Kristensen G.B., et al. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res 2005, 65:331-337.
59. Ahn S.J., Kim D.K., Kim S.S., Bae C.B., Cho H.J., Kim H.G., et al. Association between apolipoprotein E genotype, chronic liver disease, and hepatitis B virus. Clin Mol Hepatol 2012, 18:295-301.
60. Lannergard A., Larsson A., Kragsbjerg P., Friman G. Correlations between serum amyloid A protein and C-reactive protein in infectious diseases. Scand J Clin Lab Invest 2003, 63:267-272.
61. Li Y., Cai L., Wang H., Wu P., Gu W., Chen Y., et al. Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. Oncogene 2011, 30:3887-3899.
62. Sasaki M., Yoneda N., Kitamura S., Sato Y., Nakanuma Y. A serum amyloid A-positive hepatocellular neoplasm arising in alcoholic cirrhosis: a previously unrecognized type of inflammatory hepatocellular tumor. Mod Pathol 2012, 25:1584-1593.